

Supplementary Material

Quinoline Alkaloids with Anti-inflammatory Activity from *Zanthoxylum avicennae*

Kai-Long Ji,^{‡ab} Wei Liu,^{‡ab} Wei-Hang Yin,^{ab} Jing-Ya Li,^{*ab} and Jian-Min Yue^{*ab}

^a State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,
Chinese Academy of Sciences, 555 Zuchongzhi Road, Zhangjiang Hi-Tech Park,
Shanghai 201203, China

^b University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing
100049, China

Corresponding Authors:

*E-mail: jyli@simm.ac.cn (J. Y. Li) and jmyue@simm.ac.cn (J. M. Yue)

[‡] These authors contributed equally.

Table of Contents

Fig. S1 ECD spectrum of compound 1	4
Fig. S2 Chiral HPLC separation of compound 1	5
Fig. S3 Key ¹ H- ¹ H COSY and HMBC correlations of 2–6	6
Fig. S4 Chiral HPLC separation of compound 7	7
Fig. S5 ECD spectra of two enantiomers (+)- 7 and (-)- 7	8
Fig. S6 Chiral HPLC separation of compound 8	9
Fig. S7 ECD spectra of two enantiomers (+)- 8 and (-)- 8	10
Fig. S8. The effect of Compound 2–10 on the gene expression level of IL-1β in RAW264.7 cells	11
Table S1 ¹ H and ¹³ C NMR data for 5 and 6 in CDCl ₃ (δ in ppm and <i>J</i> in Hz)	12
Table S2 X-ray crystallographic data for compound 1	13
Table S3 X-ray crystallographic data for compound (-)- 1	14
Table S4 X-ray crystallographic data for compound (+)- 7	15
Table S5 Primer sequences used in RT-PCR analysis	16
Fig. S9 ¹ H NMR spectrum of 1 in CDCl ₃	17
Fig. S10 ¹³ C NMR spectrum of 1 in CDCl ₃	18
Fig. S11 HSQC spectrum of 1	19
Fig. S12 HMBC spectrum of 1	19
Fig. S13 COSY spectrum of 1	20
Fig. S14 ROESY spectrum of 1	20
Fig. S15 ESI-MS spectrum of 1	21
Fig. S16 HRESI-MS spectrum of 1	21
Fig. S17 IR spectrum of 1	22
Fig. S18 ¹ H NMR spectrum of 2 in CDCl ₃	23
Fig. S19 ¹³ C NMR spectrum of 2 in CDCl ₃	24
Fig. S20 HSQC spectrum of 2	25
Fig. S21 HMBC spectrum of 2	25
Fig. S22 COSY spectrum of 2	26
Fig. S23 ESI-MS spectrum of 2	26
Fig. S24 HRESI-MS spectrum of 2	27
Fig. S25 IR spectrum of 2	28
Fig. S26 ¹ H NMR spectrum of 3 in CDCl ₃	29
Fig. S27 ¹³ C NMR spectrum of 3 in CDCl ₃	30
Fig. S28 HSQC spectrum of 3	31
Fig. S29 HMBC spectrum of 3	31
Fig. S30 COSY spectrum of 3	32
Fig. S31 ESI-MS spectrum of 3	32
Fig. S32 HRESI-MS spectrum of 3	33
Fig. S33 IR spectrum of 3	34

Fig. S34 ^1H NMR spectrum of 4 in CDCl_3	35
Fig. S35 ^{13}C NMR spectrum of 4 in CDCl_3	36
Fig. S36 HSQC spectrum of 4	37
Fig. S37 HMBC spectrum of 4	37
Fig. S38 COSY spectrum of 4	38
Fig. S39 ESI-MS spectrum of 4	38
Fig. S40 HRESI-MS spectrum of 4	39
Fig. S41 IR spectrum of 4	40
Fig. S42 ^1H NMR spectrum of 5 in CDCl_3	41
Fig. S43 ^{13}C NMR spectrum of 5 in CDCl_3	42
Fig. S44 HSQC spectrum of 5	43
Fig. S45 HMBC spectrum of 5	43
Fig. S46 COSY spectrum of 5	44
Fig. S47 ESI-MS spectrum of 5	44
Fig. S48 HRESI-MS spectrum of 5	45
Fig. S49 IR spectrum of 5	46
Fig. S50 ^1H NMR spectrum of 6 in CDCl_3	47
Fig. S51 ^{13}C NMR spectrum of 6 in CDCl_3	48
Fig. S52 HSQC spectrum of 6	49
Fig. S53 HMBC spectrum of 6	49
Fig. S54 COSY spectrum of 6	50
Fig. S55 ROESY spectrum of 6	50
Fig. S56 ESI-MS spectrum of 6	51
Fig. S57 HRESI-MS spectrum of 6	51
Fig. S58 IR spectrum of 6	52
Fig. S59 ^1H NMR spectrum of (+)- 7 in CD_3OD	53
Fig. S60 ^{13}C NMR spectrum of (+)- 7 in CD_3OD	54
Fig. S61 ^1H NMR spectrum of (-)- 7 in CD_3OD	55
Fig. S62 HSQC spectrum of 7	56
Fig. S63 HSQC spectrum of 7	56
Fig. S64 COSY spectrum of 7	57
Fig. S65. ESI-MS spectrum of 7	57
Fig. S66 HRESI-MS spectrum of 7	58
Fig. S67 ^1H NMR spectrum of (+)- 8 in CDCl_3	59
Fig. S68 ^{13}C NMR spectrum of (+)- 8 in CDCl_3	60
Fig. S69 ^1H NMR spectrum of (-)- 8 in CDCl_3	61
Fig. S70 ESI-MS spectrum of 8	62





Fig. S1 ECD spectrum of compound **1**

Fig. S2 Chiral HPLC separation of compound **1**



	名称	保留时间 (分钟)	面积 (微伏*秒)	% 面积	高度 (微伏)	% 高度
1	峰1	7.958	8821112	22.84	621627	26.75
2	峰2	8.882	29806245	77.16	1701961	73.25

*Lux[®] Amylose-1 (250 mm × 10 mm, S-5 μm) LC column (UV = 254 nm)

Mobile Phase: n-hexane/isopropanol 7:3, v/v, 3ml.min⁻¹

(+)-**1**:(-)-**1** ≈ 3:1





Fig. S3 Key ^1H - ^1H COSY and HMBC correlations of 2–6

Fig. S4 Chiral HPLC separation of compound **7**



	名称	保留时间 (分钟)	面积 (微伏*秒)	% 面积	高度 (微伏)	% 高度
1	峰1	9.301	13193340	53.41	847704	55.38
2	峰2	10.144	11507906	46.59	682928	44.62

*Lux[®] Amylose-1 (250 mm × 10 mm, S-5 μm) LC column (UV = 254 nm)

Mobile Phase: n-hexane/isopropanol 85:15, v/v, 3ml.min⁻¹

(+)-7:(-)-7 ≈ 1:1





Fig. S5 ECD spectra of two enantiomers (+)-7 and (-)-7

Fig. S6 Chiral HPLC separation of compound **8**



	名称	保留时间 (分钟)	面积 (微伏*秒)	% 面积	高度 (微伏)	% 高度
1	峰1	15.276	9366728	51.44	394037	54.27
2	峰2	17.235	8841126	48.56	332092	45.73

*Lux[®] Amylose-1 (250 mm × 10 mm, S-5 μm) LC column (UV = 254 nm)

Mobile Phase: n-hexane/isopropanol 7:3, v/v, 3ml.min⁻¹

(+)-8:(-)-8 ≈ 1:1




Fig. S7 ECD spectra of two enantiomers (+)-**8** and (-)-**8**.




Fig. S8. The effect of Compound 2–10 on the gene expression level of IL-1 β in RAW264.7 cells. The results are shown as the mean \pm s.e.m., n=3. Data were analyzed by student's T-test (two-tailed). *P < 0.05 compared with the Ctrl group. The Ctrl (Control) group means RAW264.7 macrophages were treated with LPS (100 ng/mL) but without compounds.

Table S1 ^1H and ^{13}C NMR data for **5** and **6** in CDCl_3 (δ in ppm and J in Hz)

No.	5 ^a		6 ^b	
	δ_{H}	δ_{C}	δ_{H}	δ_{C}
2		154.1		154.7
3	6.20 s	111.6	6.25 s	111.5
4		178.0		178.0
4a		126.7		126.8
5	8.44 dd (7.6, 1.5)	126.8	8.46 dd (7.6, 1.7)	126.9
6	7.38 t (7.6)	123.6	7.38 t (7.6)	123.5
7	7.67 ddd (8.6, 7.6, 1.5)	132.3	7.67 ddd (8.7, 7.6, 1.7)	132.2
8	7.54 d (8.6)	115.6	7.51 (8.7)	115.4
8a		142.2		142.1
1'	2.73 m (2H)	34.4	2.72 m (2H)	34.1
2'	1.96 m (2H)	22.4	1.76 m (2H)	28.5
3'	2.58 t (6.3) (2H)	41.2	2.14 m (2H)	32.0
4'		210.4	5.40 dt (14.5, 6.8)	127.5
5'	2.39 t (7.3) (2H)	45.1	5.54 dt (14.5, 6.4)	134.1
6'	1.59 m (2H)	17.4	2.02 m (2H)	25.7
7'	0.91 t (7.3)	13.9	0.98 t (7.5)	14.1
N-Me	3.84 s	34.5	3.74 s	34.3

^a NMR data was recorded at 400 MHz (^1H) and 125 MHz (^{13}C). ^b NMR data was recorded at 600 MHz (^1H) and 150 MHz (^{13}C).

Table S2 X-ray crystallographic data for compound **1**

Empirical formula	$C_{16}H_{19}NO_5^a$
Formula weight	305.32
Temperature	170.02 K
Wavelength	1.34139 Å
Crystal system	Triclinic
Space group	P-1
Unit cell dimensions	$a = 8.5101(3)$ Å $\alpha = 77.6570(10)^\circ$. $b = 9.0807(3)$ Å $\beta = 83.0550(10)^\circ$. $c = 9.5903(3)$ Å $\gamma = 88.4020(10)^\circ$.
Volume	718.67(4) Å ³
Z	2
Density (calculated)	1.411 Mg/m ³
Absorption coefficient	0.561 mm ⁻¹
F(000)	324
Crystal size	0.12 x 0.1 x 0.08 mm ³
Theta range for data collection	4.134 to 55.059°.
Index ranges	-10 ≤ h ≤ 10, -11 ≤ k ≤ 11, -11 ≤ l ≤ 11
Reflections collected	15698
Independent reflections	2729 [R(int) = 0.0540]
Completeness to theta = 53.594°	99.5 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.7508 and 0.5779
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	2729 / 0 / 207
Goodness-of-fit on F ²	1.046
Final R indices [I > 2σ(I)]	R1 = 0.0391, wR2 = 0.1024
R indices (all data)	R1 = 0.0425, wR2 = 0.1055
Extinction coefficient	n/a
Largest diff. peak and hole	0.253 and -0.251 e.Å ⁻³
CCDC number	2160133

^a Crystals of compound **1** were obtained from MeOH.

Table S3 X-ray crystallographic data for compound (-)-**1**

Empirical formula	$C_{15}H_{17}NO_5^a$
Formula weight	291.29
Temperature	170.04 K
Wavelength	1.34139 Å
Crystal system	Monoclinic
Space group	P 1 21 1
Unit cell dimensions	$a = 9.7252(4)$ Å $\alpha = 90^\circ$ $b = 7.2357(3)$ Å $\beta = 98.737(2)^\circ$ $c = 10.0005(4)$ Å $\gamma = 90^\circ$
Volume	$695.56(5)$ Å ³
Z	2
Density (calculated)	1.391 Mg/m ³
Absorption coefficient	0.563 mm ⁻¹
F(000)	308
Crystal size	0.12 x 0.08 x 0.06 mm ³
Theta range for data collection	5.996 to 55.068°.
Index ranges	-11 ≤ h ≤ 11, -8 ≤ k ≤ 8, -12 ≤ l ≤ 12
Reflections collected	9299
Independent reflections	2585 [R(int) = 0.0640]
Completeness to theta = 53.594°	99.0 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.7508 and 0.5615
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	2585 / 1 / 201
Goodness-of-fit on F ²	1.051
Final R indices [I > 2σ(I)]	R1 = 0.0351, wR2 = 0.0812
R indices (all data)	R1 = 0.0401, wR2 = 0.0869
Absolute structure parameter	0.11(16)
Extinction coefficient	n/a
Largest diff. peak and hole	0.159 and -0.178 e.Å ⁻³
CCDC number	2160134

^a Crystals of compound (-)-**1** were obtained from MeOH.

Table S4 X-ray crystallographic data for compound (+)-7

Empirical formula	C ₁₅ H ₁₇ NO ₄
Formula weight	275.29
Temperature	169.99 K
Wavelength	1.34139 Å
Crystal system	Monoclinic
Space group	P 1 21 1
Unit cell dimensions	a = 8.5948(3) Å α = 90°. b = 8.5216(3) Å β = 100.0350(10)°. c = 18.7212(6) Å γ = 90°.
Volume	1350.19(8) Å ³
Z	4
Density (calculated)	1.354 Mg/m ³
Absorption coefficient	0.522 mm ⁻¹
F(000)	584
Crystal size	0.12 x 0.1 x 0.08 mm ³
Theta range for data collection	4.545 to 54.944°.
Index ranges	-10 ≤ h ≤ 10, -10 ≤ k ≤ 10, -22 ≤ l ≤ 22
Reflections collected	14913
Independent reflections	5038 [R(int) = 0.0437]
Completeness to theta = 53.594°	98.7 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.7508 and 0.6254
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	5038 / 1 / 371
Goodness-of-fit on F ²	1.065
Final R indices [I > 2σ(I)]	R1 = 0.0331, wR2 = 0.0843
R indices (all data)	R1 = 0.0361, wR2 = 0.0874
Absolute structure parameter	0.02(9)
Extinction coefficient	n/a
Largest diff. peak and hole	0.192 and -0.173 e.Å ⁻³
CCDC number	2160135

^a Crystals of compound (+)-7 were obtained from MeOH.

Table S5 Primer sequences used in RT-PCR analysis

Genes	Forward primer	Reverse primer
<i>β-actin</i>	TGGTACCACAGGCATTGTGAT	TGATGTCACGCACGATTTCCCT
<i>Il1b</i>	GCAACTG TTCCTGAACTCAACT	ATCTTTTGGGGTCCGTCAACT
<i>Il6</i>	TAGTCCTTCCTACCCCAATTTC	TTGGTCCTTAGCCACTCCTTC

Fig. S9 ¹H NMR spectrum of **1** in CDCl₃




Fig. S10 ^{13}C NMR spectrum of **1** in CDCl_3




Fig. S11 HSQC spectrum of **1**




Fig. S12 HMBC spectrum of **1**




Fig. S13 COSY spectrum of **1**




Fig. S14 ROESY spectrum of **1**




Fig. S15 ESI-MS spectrum of **1**




Fig. S16 HRESI-MS spectrum of **1**




Fig. S17 IR spectrum of **1**




Fig. S18 ¹H NMR spectrum of **2** in CDCl₃




Fig. S19 ^{13}C NMR spectrum of **2** in CDCl_3




Fig. S20 HSQC spectrum of 2




Fig. S21 HMBC spectrum of 2




Fig. S22 COSY spectrum of 2




Fig. S23 ESI-MS spectrum of 2




Fig. S24 HRESI-MS spectrum of **2**




Fig. S25 IR spectrum of **2**




Fig. S26 ¹H NMR spectrum of **3** in CDCl₃




Fig. S27 ^{13}C NMR spectrum of **3** in CDCl_3




Fig. S28 HSQC spectrum of **3**




Fig. S29 HMBC spectrum of **3**




Fig. S30 COSY spectrum of 3




Fig. S31 ESI-MS spectrum of 3




Fig. S32 HRESI-MS spectrum of **3**




Fig. S33 IR spectrum of **3**




Fig. S34 ¹H NMR spectrum of **4** in CDCl₃




Fig. S35 ^{13}C NMR spectrum of **4** in CDCl_3




Fig. S36 HSQC spectrum of **4**




Fig. S37 HMBC spectrum of **4**




Fig. S38 COSY spectrum of 4




Fig. S39 ESI-MS spectrum of 4




Fig. S40 HRESI-MS spectrum of **4**




Fig. S41 IR spectrum of 4




Fig. S42 ¹H NMR spectrum of **5** in CDCl₃




Fig. S43 ^{13}C NMR spectrum of **5** in CDCl_3




Fig. S44 HSQC spectrum of **5**




Fig. S45 HMBC spectrum of **5**




Fig. S46 COSY spectrum of 5




Fig. S47 ESI-MS spectrum of 5




Fig. S48 HRESI-MS spectrum of **5**




Fig. S49 IR spectrum of **5**




Fig. S50 ¹H NMR spectrum of **6** in CDCl₃




Fig. S51 ^{13}C NMR spectrum of **6** in CDCl_3




Fig. S52 HSQC spectrum of **6**




Fig. S53 HMBC spectrum of **6**




Fig. S54 COSY spectrum of **6**




Fig. S55 ROESY spectrum of **6**




Fig. S56 ESI-MS spectrum of **6**





Fig. S57 HRESI-MS spectrum of **6**

Qualitative Analysis Report

Data Filename	ESIH_20190709_YJM_JKL_03.d	Sample Name	JAZ-4-B1
Sample Type	Sample	Position	P1-A2
Instrument Name	Agilent G6520 Q-TOF	Acq Method	20160322_MS_ESIH_POS_1min.m
Acquired Time	7/9/2019 15:13:57	IRM Calibration Status	Success
DA Method	small molecular data analysis method.m	Comment	ESIH by ZZY

User Spectra



Formula Calculator Results

m/z	Calc m/z	Diff (mDa)	Diff (ppm)	Ion Formula	Ion
256.1697	256.1696	-0.06	-0.24	C17 H22 N O	(M+H) ⁺

--- End Of Report ---

Fig. S58 IR spectrum of 6




Fig. S59 ¹H NMR spectrum of (+)-7 in CD₃OD




Fig. S60 ^{13}C NMR spectrum of (+)-7 in CD_3OD




Fig. S61 ¹H NMR spectrum of (-)-7 in CD₃OD




Fig. S62 HSQC spectrum of 7




Fig. S63 HSQC spectrum of 7




Fig. S64 COSY spectrum of 7




Fig. S65. ESI-MS spectrum of 7

ESIL_20190830_YJM_JKL_14 #11-12 RT: 0.17-0.19 AV: 2 SB: 9 0.02-0.06, 0.94-1.00 NL: 3.89E6
T: ITMS + c ESI Full ms [50.00-2000.00]





Fig. S66 HRESI-MS spectrum of **7**

Qualitative Analysis Report

Data Filename	ESI_H_20190830_YJM_JKL_13.d	Sample Name	JAZ-6-5B
Sample Type	Sample	Position	P1-B7
Instrument Name	Agilent G6520 Q-TOF	Acq Method	20160322_MS_ESIH_POS_1min.m
Acquired Time	8/30/2019 20:01:05	IRM Calibration Status	Success
DA Method	small molecular data analysis method.m	Comment	ESI_H by ZZY

User Spectra



Formula Calculator Results

m/z	Calc m/z	Diff (mDa)	Diff (ppm)	Ion Formula	Ion
276.1235	276.123	-0.42	-1.51	C15 H18 N O4	(M+H)+

--- End Of Report ---

Fig. S67 ¹H NMR spectrum of (+)-**8** in CDCl₃




Fig. S68 ^{13}C NMR spectrum of (+)-**8** in CDCl_3




Fig. S69 ¹H NMR spectrum of (-)-**8** in CDCl₃




Fig. S70 ESI-MS spectrum of **8**

ESIL_20190830_YJM_JKL_15 #31-32 RT: 0.47-0.49 AV: 2 SB: 9 0.02-0.06 , 0.93-0.99 NL: 5.18E6
T: ITMS + c ESI Full ms [50.00-2000.00]

